cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.6084/m9.figshare.28428893
title: Supplementary Material for: SEX DIFFERENCES IN MARKERS OF CEREBRAL SMALL VESSEL DISEASE IN PATIENTS WITH LOBAR INTRACEREBRAL HEMORRHAGE

description: Introduction: Cerebral small vessel disease (CSVD) is a major cause of primary lobar intracerebral hemorrhage (ICH) due to cerebral amyloid angiopathy (CAA) or hypertensive arteriopathy (HA). Sex differences in CSVD imaging markers and prevalence of CAA vs HA in lobar ICH remain unexplored.

Methods: We performed a retrospective analysis of patients with primary lobar ICH who underwent MRI during hospitalization. We collected demographic, clinical, and outcome data. We reviewed MRIs for CSVD markers and calculated composite CSVD burden score (cCSVDbs). We assigned possible/probable CAA using Boston criteria 2.0. We grouped patients based on their sex and examined associations between sex and CSVD markers, cCSVDbs, or CAA. Kaplan Meier survival analysis was used to determine ICH-onset age among patients with first-ever symptomatic lobar ICH.

Results: 214 patients were included (102 (47.66%) women). Men were more likely to be current alcohol abusers (25.69%vs9.09%, p=0.002), current smokers (24.30%vs12.12%, p=0.024), and have coronary artery disease (26.79%vs15.69%, p=0.048), and hyperglycemia on admission (142.79±59.59vs126.58±37.29, p=0.019). Women were older (74.91±11.69vs69.28±14.53 years, p=0.002), and more likely to have possible/probable CAA in univariate (97.06%vs88.39%; OR 4.33, 95%CI 1.19-15.67; p=0.025) but not multivariate analysis. We found no significant differences in MRI markers of CSVD, cCSVDbs, or CAA. Among patients who presented with their first-ever primary symptomatic lobar ICH (n=187), men were younger than women (73vs77 years, p=0.001).

Conclusions: In our cohort of patients with primary lobar ICH, we found no significant difference in clinical and imaging characteristics between sexes. However, men were more likely to have a younger lobar ICH-onset age compared to women.
DOI: 10.6084/m9.figshare.28428893.v1
title: Supplementary Material for: SEX DIFFERENCES IN MARKERS OF CEREBRAL SMALL VESSEL DISEASE IN PATIENTS WITH LOBAR INTRACEREBRAL HEMORRHAGE

description: Introduction: Cerebral small vessel disease (CSVD) is a major cause of primary lobar intracerebral hemorrhage (ICH) due to cerebral amyloid angiopathy (CAA) or hypertensive arteriopathy (HA). Sex differences in CSVD imaging markers and prevalence of CAA vs HA in lobar ICH remain unexplored.

Methods: We performed a retrospective analysis of patients with primary lobar ICH who underwent MRI during hospitalization. We collected demographic, clinical, and outcome data. We reviewed MRIs for CSVD markers and calculated composite CSVD burden score (cCSVDbs). We assigned possible/probable CAA using Boston criteria 2.0. We grouped patients based on their sex and examined associations between sex and CSVD markers, cCSVDbs, or CAA. Kaplan Meier survival analysis was used to determine ICH-onset age among patients with first-ever symptomatic lobar ICH.

Results: 214 patients were included (102 (47.66%) women). Men were more likely to be current alcohol abusers (25.69%vs9.09%, p=0.002), current smokers (24.30%vs12.12%, p=0.024), and have coronary artery disease (26.79%vs15.69%, p=0.048), and hyperglycemia on admission (142.79±59.59vs126.58±37.29, p=0.019). Women were older (74.91±11.69vs69.28±14.53 years, p=0.002), and more likely to have possible/probable CAA in univariate (97.06%vs88.39%; OR 4.33, 95%CI 1.19-15.67; p=0.025) but not multivariate analysis. We found no significant differences in MRI markers of CSVD, cCSVDbs, or CAA. Among patients who presented with their first-ever primary symptomatic lobar ICH (n=187), men were younger than women (73vs77 years, p=0.001).

Conclusions: In our cohort of patients with primary lobar ICH, we found no significant difference in clinical and imaging characteristics between sexes. However, men were more likely to have a younger lobar ICH-onset age compared to women.
DOI: 10.6084/m9.figshare.28428896
title: Supplementary Material for: DOT1L regulates cellular senescence during the progression from acute kidney injury to chronic kidney disease via the micro-222-5p/WNT9B signaling pathway.

description: Background: Acute kidney injury (AKI) is a common clinical condition where cellular senescence plays a crucial role in its progression. Previous studies have suggested that DOT1L plays a pivotal role in cellular senescence, yet its specific mechanisms in regulating AKI cellular senescence remain unclear.
Methods: This study utilized a glycerol-induced in vivo AKI model and employed the DOT1L-specific inhibitor EPZ004777 (EPZ) to suppress DOT1L function. Aging staining, PAS staining, and Masson staining were employed to assess renal aging, injury, and interstitial fibrosis. In vitro experiments utilized doxorubicin-treated human kidney tubular epithelial (HK-2) cells to establish an AKI cellular senescence model. EPZ was used to inhibit DOT1L, evaluating its impact on cellular senescence. High-throughput miRNA sequencing was performed to analyze differential expression of miRNAs downstream of DOT1L, and DOT1L overexpression and dual luciferase reporter gene experiments were conducted to explore interactions among DOT1L, miR-222-5p, and WNT9B.
Results: The results demonstrated that in vivo inhibition of DOT1L significantly reduced cellular senescence and improved renal tubular injury and interstitial fibrosis. In the doxorubicin -induced HK-2 cell model, DOT1L inhibition markedly decreased cellular senescence and lowered mRNA and protein levels of senescence markers, while alleviating cell cycle arrest. DOT1L inhibition notably upregulated miR-222-5p expression and suppressed WNT9B expression, with opposite effects observed with DOT1L overexpression.
Conclusion: DOT1L regulates cellular senescence through the miR-222-5p/WNT9B pathway in AKI. These findings suggest that DOT1L may serve as a potential therapeutic target to mitigate the progression of AKI to chronic kidney disease.
DOI: 10.6084/m9.figshare.28428896.v1
title: Supplementary Material for: DOT1L regulates cellular senescence during the progression from acute kidney injury to chronic kidney disease via the micro-222-5p/WNT9B signaling pathway.

description: Background: Acute kidney injury (AKI) is a common clinical condition where cellular senescence plays a crucial role in its progression. Previous studies have suggested that DOT1L plays a pivotal role in cellular senescence, yet its specific mechanisms in regulating AKI cellular senescence remain unclear.
Methods: This study utilized a glycerol-induced in vivo AKI model and employed the DOT1L-specific inhibitor EPZ004777 (EPZ) to suppress DOT1L function. Aging staining, PAS staining, and Masson staining were employed to assess renal aging, injury, and interstitial fibrosis. In vitro experiments utilized doxorubicin-treated human kidney tubular epithelial (HK-2) cells to establish an AKI cellular senescence model. EPZ was used to inhibit DOT1L, evaluating its impact on cellular senescence. High-throughput miRNA sequencing was performed to analyze differential expression of miRNAs downstream of DOT1L, and DOT1L overexpression and dual luciferase reporter gene experiments were conducted to explore interactions among DOT1L, miR-222-5p, and WNT9B.
Results: The results demonstrated that in vivo inhibition of DOT1L significantly reduced cellular senescence and improved renal tubular injury and interstitial fibrosis. In the doxorubicin -induced HK-2 cell model, DOT1L inhibition markedly decreased cellular senescence and lowered mRNA and protein levels of senescence markers, while alleviating cell cycle arrest. DOT1L inhibition notably upregulated miR-222-5p expression and suppressed WNT9B expression, with opposite effects observed with DOT1L overexpression.
Conclusion: DOT1L regulates cellular senescence through the miR-222-5p/WNT9B pathway in AKI. These findings suggest that DOT1L may serve as a potential therapeutic target to mitigate the progression of AKI to chronic kidney disease.
DOI: 10.6084/m9.figshare.28428902
title: Supplementary Material for: The Efficacy and Safety of Adjustable Intragastric Balloon for Weight Loss: a Systematic Review and Meta-Analysis

description: Introduction: Adjustable intragastric balloon (aIGB), as known as a novel minimally invasive therapy for obesity, provide a sustained alternative for weight loss. Weight loss is achieved by implanting a balloon into the patient's stomach, with the volume of the balloon being adjustable through the injection or extraction of physiological saline. Its key distinction from other intragastric balloons lies in post-implantation volume control. Currently, the efficacy and safety of aIGB have not been well described.
Methods: MEDLINE, Embase, and Cochrane Library were searched for relevant articles. Efficacy and safety of aIGB were evaluated by total body weight loss (TWL) after treatment and severe adverse events. 
Results: A total of 12 eligible studies with 4981 patients were included. The average inserting time was 9.9 months, and the pooled mean TWL was 16.4% (95%CI 0.153 - 0.175, I2 = 91.2%). The pooled prevalence of patients choosing upward balloon adjustment was 34.2% (95%CI 0.220 - 0.485, I2 = 96.5), and all reported additional weight loss with a mean of 6.3 (4.8~9.3) kg. The pooled prevalence of patients choosing downward balloon adjustment was 9.2% (95%CI 0.065 - 0.119, I2 = 73.9%), and the pooled prevalence of alleviating intolerance in these patients was 90.8% (95%CI 0.817-0.974, I2 = 53.4%). The pooled prevalence of intolerance and early removal within 3 months was 5.7% (95%CI 0.035 - 0.078, I2 = 79.8%), and the pooled prevalence of stomach ulcer was 1.1% (95%CI 0.008 - 0.014, I2 = 5.1%). There was no obvious publication bias detected for these outcomes. Leave-one-out and subgroup analysis demonstrated the results were statistically reliable.
Conclusion: aIGB has the ability of significant and sustained weight loss, and can effectively manage both intolerance and weight loss plateaus by adjusting the balloon volume during treatment.
DOI: 10.6084/m9.figshare.28428905
title: Supplementary Material for: Iatrogenic Cushing syndrome and secondary adrenal insufficiency in a child due to topical ocular corticosteroids: A case report

description: Introduction: Iatrogenic Cushing Syndrome (ICS) can be caused by synthetic glucocorticoids administered through various routes. ICS caused by corticosteroid eye drops is an exceptional event, being more frequent in pediatric age. Herein, we describe a case of iatrogenic Cushing syndrome (ICS) associated with secondary adrenal insufficiency (SAI) caused by ocular topical corticosteroid treatment.
Case presentation: An 11-year-old girl was referred to our ocular inflammation department due to idiopathic, chronic, non-hypertensive, non-granulomatous bilateral anterior uveitis, treated with topical dexamethasone (eye drops, 1mg/ml) for one year. During the past year, the child and her mother observed a gradual change in her physical appearance, particularly noting the development of a cushingoid facial appearance. Laboratory data revealed morning serum adrenocorticotropic hormone (ACTH) of 3.6 ng/L [7.2-63.3] and morning serum cortisol of 0.20 μg/dL [6.2-19.4]. She was treated with methotrexate (15 mg/week, orally), and the topical corticosteroid regimen was progressively tapered and discontinued after three months. Nine months after the patient discontinued corticosteroid eyedrops, her cushingoid face disappeared, and her laboratory data improved. Regarding the ophthalmological examination, the uveitis remained in remission with methotrexate, with no new episodes of intraocular inflammation.
Conclusion: Although rare, ophthalmologists must be aware of ICS and SAI and prioritize using the least potent corticosteroid for the shortest duration necessary. Additionally, clinicians should avoid abrupt cessation of long-term corticosteroid therapy, as this can precipitate an adrenal crisis in the presence of adrenal insufficiency.
DOI: 10.6084/m9.figshare.28428905.v1
title: Supplementary Material for: Iatrogenic Cushing syndrome and secondary adrenal insufficiency in a child due to topical ocular corticosteroids: A case report

description: Introduction: Iatrogenic Cushing Syndrome (ICS) can be caused by synthetic glucocorticoids administered through various routes. ICS caused by corticosteroid eye drops is an exceptional event, being more frequent in pediatric age. Herein, we describe a case of iatrogenic Cushing syndrome (ICS) associated with secondary adrenal insufficiency (SAI) caused by ocular topical corticosteroid treatment.
Case presentation: An 11-year-old girl was referred to our ocular inflammation department due to idiopathic, chronic, non-hypertensive, non-granulomatous bilateral anterior uveitis, treated with topical dexamethasone (eye drops, 1mg/ml) for one year. During the past year, the child and her mother observed a gradual change in her physical appearance, particularly noting the development of a cushingoid facial appearance. Laboratory data revealed morning serum adrenocorticotropic hormone (ACTH) of 3.6 ng/L [7.2-63.3] and morning serum cortisol of 0.20 μg/dL [6.2-19.4]. She was treated with methotrexate (15 mg/week, orally), and the topical corticosteroid regimen was progressively tapered and discontinued after three months. Nine months after the patient discontinued corticosteroid eyedrops, her cushingoid face disappeared, and her laboratory data improved. Regarding the ophthalmological examination, the uveitis remained in remission with methotrexate, with no new episodes of intraocular inflammation.
Conclusion: Although rare, ophthalmologists must be aware of ICS and SAI and prioritize using the least potent corticosteroid for the shortest duration necessary. Additionally, clinicians should avoid abrupt cessation of long-term corticosteroid therapy, as this can precipitate an adrenal crisis in the presence of adrenal insufficiency.
DOI: 10.6084/m9.figshare.28428908
title: Supplementary Material for: Detecting atrial fibrillation by artificial intelligence enabled neuroimaging examination.

description: Background

Diagnosis of occult atrial fibrillation (AF) is difficult as it is often asymptomatic, leading to under detection. Current diagnostic tests have variable limitations in feasibility and accuracy. Machine learning is gaining greater traction for clinical decision making and may help facilitate the detection of undiagnosed AF when applied to magnetic resonance imaging (MRI). We hypothesise that machine learning algorithm increases the accurate classification of MRIs of stroke patients into those due to AF vs large artery atherosclerosis. 

Methods 

Stroke aetiology for each patient was determined by a review of medical records and investigations. Patients with either AF or large artery atherosclerosis were included. 
Patients were randomly divided into the training and validation groups (4:1). A 3D convolutional neural network (ConvNeXt) was developed to train and validate the algorithm. After training, the models were evaluated using common metrics for binary classification. 

Results

A total of 235 patients were analysed (97 with AF, 138 without AF). The mean age of the sample was 71.1 (SD 14.2) and 35% percent were female. The best discriminative performance was obtained in the 5th fold of cross-validation (AUC-ROC 0.88) and the overall model performance was 0.81. The best performing metrics were precision (0.84) and the F1-score (0.77). 

Conclusion

Our machine learning algorithm has reasonable classification power in categorizing stroke patients into those with and without underlying AF. Testing in external validation data sets are critical to confirm these results.
DOI: 10.6084/m9.figshare.28428908.v1
title: Supplementary Material for: Detecting atrial fibrillation by artificial intelligence enabled neuroimaging examination.

description: Background

Diagnosis of occult atrial fibrillation (AF) is difficult as it is often asymptomatic, leading to under detection. Current diagnostic tests have variable limitations in feasibility and accuracy. Machine learning is gaining greater traction for clinical decision making and may help facilitate the detection of undiagnosed AF when applied to magnetic resonance imaging (MRI). We hypothesise that machine learning algorithm increases the accurate classification of MRIs of stroke patients into those due to AF vs large artery atherosclerosis. 

Methods 

Stroke aetiology for each patient was determined by a review of medical records and investigations. Patients with either AF or large artery atherosclerosis were included. 
Patients were randomly divided into the training and validation groups (4:1). A 3D convolutional neural network (ConvNeXt) was developed to train and validate the algorithm. After training, the models were evaluated using common metrics for binary classification. 

Results

A total of 235 patients were analysed (97 with AF, 138 without AF). The mean age of the sample was 71.1 (SD 14.2) and 35% percent were female. The best discriminative performance was obtained in the 5th fold of cross-validation (AUC-ROC 0.88) and the overall model performance was 0.81. The best performing metrics were precision (0.84) and the F1-score (0.77). 

Conclusion

Our machine learning algorithm has reasonable classification power in categorizing stroke patients into those with and without underlying AF. Testing in external validation data sets are critical to confirm these results.
DOI: 10.6084/m9.figshare.28428911
title: Supplementary Material for: Exploring associations between cannabis prices, stores, and usage after recreational legalization

description: Introduction: Canada legalized recreational cannabis in October 2018, but commercial retailing took time to develop. This study first explored how self-reported cannabis use prevalence, daily use, product type use, and age of initial use changed during 2019-2023. It then analyzed whether the changes were associated with rising store numbers or falling prices. 
Methods: Data on store counts, retail pricing, and cannabis use came from government reports covering 10 provinces over 5 years. Panel data linear regressions analyzed 50 province-year aggregated observations. 
Results: There were no significant changes in prevalence among males and people aged 16-24, or in the proportion using cannabis daily. Prevalence among females increased; it was negatively associated with prices. Prevalence among people aged 25+ also increased: it showed tentative negative associations with prices. Dried cannabis use decreased and was positively associated with prices. Edibles use increased and was negatively associated with prices. Mean initial age of use increased; it was negatively associated with prices and positively with stores.
Conclusion: Canada’s large cannabis retail expansion was accompanied by relatively modest usage changes, most of which showed associations with falling prices but not rising store counts.
DOI: 10.6084/m9.figshare.28428911.v1
title: Supplementary Material for: Exploring associations between cannabis prices, stores, and usage after recreational legalization

description: Introduction: Canada legalized recreational cannabis in October 2018, but commercial retailing took time to develop. This study first explored how self-reported cannabis use prevalence, daily use, product type use, and age of initial use changed during 2019-2023. It then analyzed whether the changes were associated with rising store numbers or falling prices. 
Methods: Data on store counts, retail pricing, and cannabis use came from government reports covering 10 provinces over 5 years. Panel data linear regressions analyzed 50 province-year aggregated observations. 
Results: There were no significant changes in prevalence among males and people aged 16-24, or in the proportion using cannabis daily. Prevalence among females increased; it was negatively associated with prices. Prevalence among people aged 25+ also increased: it showed tentative negative associations with prices. Dried cannabis use decreased and was positively associated with prices. Edibles use increased and was negatively associated with prices. Mean initial age of use increased; it was negatively associated with prices and positively with stores.
Conclusion: Canada’s large cannabis retail expansion was accompanied by relatively modest usage changes, most of which showed associations with falling prices but not rising store counts.
DOI: 10.6084/m9.figshare.28428914
title: Supplementary Material for: Conversion surgery after immune checkpoint inhibitor-based combination therapy for initially unresectable hepatocellular carcinoma: A retrospective cohort study

description: Introduction: Hepatocellular carcinoma (HCC) has a high incidence rate and is often asymptomatic in its early stages. Combination therapies using immune checkpoint inhibitors (ICIs) have demonstrated survival benefits and high objective response rates, offering hope for conversion surgery in patients with initially unresectable HCC. We aimed to investigate the oncological outcomes of conversion surgery compared to those with continuing systemic treatment alone in patients who responded well to ICIs-based therapy, as well as the surgical outcomes associated with conversion surgery.

Methods: We consecutively enrolled patients diagnosed with HCC between January 1, 2019 and February 1, 2024. These patients received treatment with ICIs combined with either anti-VEGF antibodies or tyrosine kinase inhibitors. Tumor response and resectability were assessed every 2 months. Patients who responded positively and met the criteria for conversion surgery were included. 

Results: Among 613 patients with initially unresectable HCC, 128 achieved conversion and met the surgical resection criteria during combination therapy. Of these, 54 continued non-surgical comprehensive treatment, 74 underwent conversion surgery, and 57 continued their original treatment post-surgery. The median follow-up time was 24.1 and 42.5 months for the surgery and non-surgery groups, respectively. The median PFS was 29.4 months in the surgery group versus 11.2 months in the non-surgery group (P&lt;0.0001, hazard ratio [HR]=0.39 [0.24–0.63]). The median OS was not reached in the surgery group, compared to 25.4 months in the non-surgery group (P&lt;0.0001, HR=0.26 [0.14–0.46]). Multivariate Cox regression analysis indicated that conversion surgery was independently associated with improved OS and PFS (P&lt;0.001), and continuing the original treatment post-surgery significantly influenced OS and recurrence -free survival.

Conclusion: Conversion surgery after meeting the surgical criteria during immunotherapy provides significant prognostic benefits for patients with initially unresectable HCC, demonstrating high safety and R0 resection rates. For those undergoing conversion surgery, promptly resuming the original treatment after surgery is necessary.
DOI: 10.15468/dl.dxdy2p
title: Occurrence Download

description: A dataset listing the 2029 species recorded in GBIF matching the query:
{
 "DatasetKey" : [
 "is Inventario Español de Especies Terrestres (MAGRAMA)"
 ]
}

 The dataset's 2029 records were derived from 1 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0002762-250214102907787/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.